Protective role of sodium-glucose co-transporter 2 inhibition against vascular complications in diabetes

Rejuvenation Research

Volumn 19, Issue 2, 2016, Pages 107-114

  Yamagishi, Sho Ichi ^a   Matsui, Takanori ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INSULIN; SODIUM GLUCOSE COTRANSPORTER 2; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; URIC ACID; CARDIOTONIC AGENT;

APOPTOSIS; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED CLINICAL TRIAL (TOPIC); CORONARY ARTERY ATHEROSCLEROSIS; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC PATIENT; DIABETIC RETINOPATHY; GLOMERULUS; GLUCOSE URINE LEVEL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INFLAMMATION; KIDNEY TUBULE ABSORPTION; META ANALYSIS (TOPIC); NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; SYSTEMATIC REVIEW (TOPIC); URIC ACID BLOOD LEVEL; URINARY EXCRETION; WEIGHT GAIN; COMPLICATION; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; RISK FACTOR;

CARDIOTONIC AGENTS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; HUMANS; RISK FACTORS; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 84964743282     PISSN: 15491684     EISSN: 15578577     Source Type: Journal    
DOI: 10.1089/rej.2015.1738     Document Type: Article

References (94)

1. Yamagishi S, Imaizumi T. Diabetic vascular complications: Pathophysiology, biochemical basis, and potential therapeutic strategy. Curr Pharm Des 2005; 11: 2279-2299
2. Brownlee M. Biochemistry, and molecular cell biology of diabetic complications. Nature 2001; 414: 813-820
3. Dash SN, Dash NR, Guru B, Mohapatra PC. Towards reaching the target: Clinical application of mesenchymal stem cells for diabetic foot ulcers. Rejuvenation Res 2014; 17: 40-53
4. Zeadin MG, Petlura CI, Werstuck GH. Molecular mechanisms linking diabetes to the accelerated development of atherosclerosis. Can J Diabetes 2013; 37: 345-350
5. Paneni F, Beckman JA, Creager MA, Cosentino F. Diabetes, and vascular disease: Pathophysiology, clinical consequences, and medical therapy: Part I. Eur Heart J 2013; 34: 2436-2443
6. Yamagishi S. Role of advanced glycation end products (AGEs), and receptor for AGEs (RAGE) in vascular damage in diabetes. Exp Gerontol 2011; 46: 217-224
7. Kajikawa M, Nakashima A, Fujimura N, Maruhashi T, Iwamoto Y, Iwamoto A, Matsumoto T, Oda N, Hidaka T, Kihara Y, Chayama K, Goto C, Aibara Y, Noma K, Takeuchi M, Matsui T, Yamagishi S, Higashi Y. Ratio of serum levels of AGEs to soluble form of RAGE is a predictor of endothelial function. Diabetes Care 2015; 38: 119-125
8. Ishibashi Y, Matsui T, Ueda S, Fukami K, Yamagishi S. Advanced glycation end products potentiate citrated plasmaevoked oxidative, and inflammatory reactions in endothelial cells by up-regulating protease-activated receptor-1 expression. Cardiovasc Diabetol 2014; 13: 60
9. Emerging Risk Factors Collaboration, Seshasai SR, Kaptoge S, Thompson A, Di Angelantonio E, Gao P, Sarwar N, Whincup PH, Mukamal KJ, Gillum RF, Holme I, Njølstad I, Fletcher A, Nilsson P, Lewington S, Collins R, Gudnason V, Thompson SG, Sattar N, Selvin E, Hu FB, Danesh J. Diabetes mellitus, fasting glucose, and risk of causespecific death. N Engl J Med 2011; 364: 829-841
10. Livingstone SJ, Levin D, Looker HC, Lindsay RS, Wild SH, Joss N, Leese G, Leslie P, McCrimmon RJ, Metcalfe W, McKnight JA, Morris AD, Pearson DW, Petrie JR, Philip S, Sattar NA, Traynor JP, Colhoun HM; Scottish Diabetes Research Network epidemiology group; Scottish Renal Registry. Estimated life expectancy in a Scottish cohort with type 1 diabetes, 2008-2010. JAMA 2015; 313: 37-44
11. Loukine L, Waters C, Choi BC, Ellison J. Impact of diabetes mellitus on life expectancy, and health-adjusted life expectancy in Canada. Popul Health Metr 2012; 10: 7
12. Rhodes ET, Prosser LA, Hoerger TJ, Lieu T, Ludwig DS, Laffel LM. Estimated morbidity, and mortality in adolescents, and young adults diagnosed with type 2 diabetes mellitus. Diabet Med 2012; 29: 453-463
13. The Diabetes Control, and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development, and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986
14. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment, and risk complications in patients with type 2 diabetes (UKPS 33). Lancet 1998; 352: 837-853
15. Ray KK, Seshasai SR, Wijesuriya S, Sivakumaran R, Nethercott S, Preiss D, Erqou S, Sattar N. Effect of intensive control of glucose on cardiovascular outcomes, and death in patients with diabetes mellitus: A meta-analysis of randomised controlled trials. Lancet 2009; 373: 1765-1772
16. Lee YJ, Lee YJ, Han HJ. Regulatory mechanims of Na+/glucose cotransporters in renal proximal tubule cells. Kidney Int 2007; 72: 527-535
17. Sabolic I, Vrhovac I, Eror DB, Gerasimova M, Rose M, Breljak D, Ljubojevic M, Brzica H, Sebastiani A, Thal SC, Sauvant C, Kipp H, Vallon V, Koepsell H. Expression of Na+-D-glucose cotransporter SGLT2 in rodents is kidneyspecific, and exhibits sex, and species differences. Am J Physiol Cell Physiol 2012; 302: C1174-C1188
18. Santer R, Calado J. Familial renal glucosuria, and SGLT2: From a mendelian trait to a therapeutic target. Clin J Am Soc Nephrol 2010; 5: 133-141
19. Bailey CJ, Gross JL, Pieters A, Bastien A, List JF. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycemic control with metformin: A randomized, double-blind, placebo-controlled trial. Lancet 2010; 375: 2223-2233
20. Mikhail N. Place of sodium-glucose co-transporter type 2 inhibitors for treatment of type 2 diabetes. World J Diabetes 2014; 5: 854-859
21. Maliha G, Townsend RR. SGLT2 inhibitors: Their potential reduction in blood pressure. J Am Soc Hypertens 2015: 9: 48-53
22. Musso G, Gambino R, Cassader M, Pagano G. A novel approach to control hyperglycemia in type 2 diabetes: Sodium glucose co-transport (SGLT) inhibitors: Systematic review, and meta-analysis of randomized trials. Ann Med 2012; 44: 375-393
23. Guthrie RM. Sodium-glucose co-transporter 2 inhibitors, and the potential for cardiovascular risk reduction in patients with type 2 diabetes mellitus. Postgrad Med 2013; 125: 21-32
24. Yamagishi S, Matsui T. Advanced glycation end products, oxidative stress, and diabetic nephropathy. Oxid Med Cell Longev 2010; 3: 101-108
25. Fukami K, Taguchi K, Yamagishi S, Okuda S. Receptor for advanced glycation endproducts, and progressive kidney disease. Curr Opin Nephrol Hypertens 2015; 24: 54-60
26. Taft JL, Nolan CJ, Yeung SP, Hewitson TD, Martin FI. Clinical, and histological correlations of decline in renal function in diabetic patients with proteinuria. Diabetes 1994; 43: 1046-1051
27. Ziyadeh FN, Goldfarb S. The renal tubulointerstitium in diabetes mellitus. Kidney Int 1991; 39: 464-475
28. Vlassara H, Palace MR. Diabetes, and advanced glycation endproducts. J Intern Med 2002; 251: 87-101
29. Bierhaus A, Humpert PM, Morcos M, Wendt T, Chavakis T, Arnold B, Stern DM, Nawroth PP. Understanding RAGE, the receptor for advanced glycation end products. J Mol Med (Berl) 2005; 83: 876-886
30. Yamagishi S, Nakamura K, Matsui T, Ueda S, Fukami K, Okuda S. Agents that block advanced glycation end product (AGE)-RAGE (receptor for AGEs)-oxidative stress system: A novel therapeutic strategy for diabetic vascular complications. Expert Opin Investig Drugs 2008; 17: 983-996
31. Forbes JM, Cooper ME. Glycation in diabetic nephropathy. Amino Acids 2012; 42: 1185-1192
32. Manigrasso MB, Juranek J, Ramasamy R, Schmidt AM. Unlocking the biology of RAGE in diabetic microvascular complications. Trends Endocrinol Metab 2014; 25: 15-22
33. Maeda S, Matsui T, Takeuchi M, Yamagishi S. Sodiumglucose cotransporter 2-mediated oxidative stress augments advanced glycation end products-induced tubular cell apoptosis. Diabetes Metab Res Rev 2013; 29: 406-412
34. Kitada K, Nakano D, Ohsaki H, Hitomi H, Minamino T, Yatabe J, Felder RA, Mori H, Masaki T, Kobori H, Nishiyama A. Hyperglycemia causes cellular senescence via a SGLT2-and p21-dependent pathway in proximal tubules in the early stage of diabetic nephropathy. J Diabetes Complications 2014; 28: 604-611
35. Vallon V, Rose M, Gerasimova M, Satriano J, Platt KA, Koepsell H, Cunard R, Sharma K, Thomson SC, Rieg T. Knockout of Na-glucose transporter SGLT2 attenuates hyperglycemia, and glomerular hyperfiltration but not kidney growth or injury in diabetes mellitus. Am J Physiol Renal Physiol 2013; 304: F156-F167
36. Osorio H, Coronel I, Arellano A, Pacheco U, Bautista R, Franco M, Escalante B. Sodium-glucose cotransporter inhibition prevents oxidative stress in the kidney of diabetic rats. Oxid Med Cell Longev 2012; 2012: 542042
37. Malatiali S, Francis I, Barac-Nieto M. Phlorizin prevents glomerular hyperfiltration but not hypertrophy in diabetic rats. Exp Diabetes Res 2008; 2008: 305403
38. Pei F, Li BY, Zhang Z, Yu F, Li XL, Lu WD, Cai Q, Gao HQ, Shen L. Beneficial effects of phlorizin on diabetic nephropathy in diabetic db/db mice. J Diabetes Complications 2014; 28: 596-603
39. Cheng MF, Chen LJ, Wang MC, Hsu CT, Cheng JT. Decrease of FGF receptor (FGFR), and interstitial fibrosis in the kidney of streptozotocin-induced diabetic rats. Horm Metab Res 2014; 46: 1-7
40. Panchapakesan U, Pegg K, Gross S, Komala MG, Mudaliar H, Forbes J, Pollock C, Mather A. Effects of SGLT2 inhibition in human kidney proximal tubular cells-renoprotection in diabetic nephropathy? PLoS One 2013; 8: e54442
41. Gembardt F, Bartaun C, Jarzebska N, Mayoux E, Todorov VT, Hohenstein B, Hugo C. The SGLT2 inhibitor empagliflozin ameliorates early features of diabetic nephropathy in BTBR ob/ob type 2 diabetic mice with, and without hypertension. Am J Physiol Renal Physiol 2014; 307: F317-F325
42. Vallon V, Gerasimova M, Rose MA, Masuda T, Satriano J, Mayoux E, Koepsell H, Thomson SC, Rieg T. SGLT2 inhibitor empagliflozin reduces renal growth, and albuminuria in proportion to hyperglycemia, and prevents glomerular hyperfiltration in diabetic Akita mice. Am J Physiol Renal Physiol 2014; 306: F194-F204
43. Ojima A, Matsui T, Nishino Y, Nakamura N, Yamagishi S. Empagliflozin, an inhibitor of sodium-glucose cotransporter 2 exerts anti-inflammatory, and anti-fibrotic effects on experimental diabetic nephropathy partly by suppressing AGEs-receptor axis. Horm Metab Res 2015; doi: 10.1055/s-0034-1395609
44. Gangadharan Komala M, Gross S, Mudaliar H, Huang C, Pegg K, Mather A, Shen S, Pollock CA, Panchapakesan U. Inhibition of kidney proximal tubular glucose reabsorption does not prevent against diabetic nephropathy in type 1 diabetic eNOS knockout mice. PLoS One 2014; 9: e108994
45. Jerums G, Premaratne E, Panagiotopoulos S, MacIsaac RJ. The clinical significance of hyperfiltration in diabetes. Diabetologia 2010; 53: 2093-2104
46. Cherney DZ, Perkins BA, Soleymanlou N, Maione M, Lai V, Lee A, Fagan NM, Woerle HJ, Johansen OE, Broedl UC, von Eynatten M. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 2014; 129: 587-597
47. Thomson SC, Rieg T, Miracle C, Mansoury H, Whaley J, Vallon V, Singh P. Acute, and chronic effects of SGLT2 blockade on glomerular, and tubular function in the early diabetic rat. Am J Physiol Regul Integr Comp Physiol 2012; 302: R75-R83
48. Thomas MC. Renal effects of dapagliflozin in patients with type 2 diabetes. Ther Adv Endocrinol Metab 2014; 5: 53-61
49. Terami N, Ogawa D, Tachibana H, Hatanaka T, Wada J, Nakatsuka A, Eguchi J, Horiguchi CS, Nishii N, Yamada H, Takei K, Makino H. Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis, and diabetic nephropathy in db/db mice. PLoS One 2014; 24: e100777
50. Ishibashi Y, Matsui T, Yamagishi S. Tofogliflozin, a highly selective inhibitor of SGLT2 blocks proinflammatory, and proapoptotic effects of glucose overload on proximal tubular cells partly by suppressing oxidative stress generation. Horm Metab Res 2015; doi: 10.1055/s-0035-1555791
51. Nagata T, Fukuzawa T, Takeda M, Fukazawa M, Mori T, Nihei T, Honda K, Suzuki Y, Kawabe Y. Tofogliflozin, a novel sodium-glucose co-transporter 2 inhibitor, improves renal, and pancreatic function in db/db mice. Br J Pharmacol 2013; 170: 519-531
52. Suzuki M, Hiramatsu M, Fukazawa M, Matsumoto M, Honda K, Suzuki Y, Kawabe Y. Effect of SGLT2 inhibitors in a murine model of urinary tract infection with Candida albicans. Diabetes Obes Metab 2014; 16: 622-627
53. Kojima N, Williams JM, Takahashi T, Miyata N, Roman RJ. Effects of a new SGLT2 inhibitor, luseogliflozin, on diabetic nephropathy in T2DN rats. J Pharmacol Exp Ther 2013; 345: 464-472
54. Osorio H, Coronel I, Arellano A, Franco M, Escalante B, Bautista R. Ursodeoxycholic acid decreases sodium-glucose cotransporter (SGLT2) expression, and oxidative stress in the kidney of diabetic rats. Diabetes Res Clin Pract 2012; 97: 276-282
55. Bautista R, Manning R, Martinez F, Avila-Casado Mdel C, Soto V, Medina A, Escalante B. Angiotensin II-dependent increased expression of Na+-glucose cotransporter in hypertension. Am J Physiol Renal Physiol 2004; 286: F127-F133
56. Osorio H, Bautista R, Rios A, Franco M, Santamaría J, Escalante B. Effect of treatment with losartan on salt sensitivity, and SGLT2 expression in hypertensive diabetic rats. Diabetes Res Clin Pract 2009; 86: e46-e49
57. De Nicola L, Gabbai FB, Liberti ME, Sagliocca A, Conte G, Minutolo R. Sodium/glucose cotransporter 2 inhibitors, and prevention of diabetic nephropathy: Targeting the renal tubule in diabetes. Am J Kidney Dis 2014; 64: 16-24
58. Skrtić M, Cherney DZ. Sodium-glucose cotransporter-2 inhibition, and the potential for renal protection in diabetic nephropathy. Curr Opin Nephrol Hypertens 2015; 24: 96-103
59. Unno K, Yamamoto H, Toda M, Hagiwara S, Iguchi K, Hoshino M, Takabayashi F, Hasegawa-Ishii S, Shimada A, Hosokawa M, Higuchi K, Mori M. Novel frame-shift mutation in Slc5a2 encoding SGLT2 in a strain of senescenceaccelerated mouse SAMP10. Biochem Biophys Res Commun 2014; 454: 89-94
60. Duprez DA, Cohn JN. Arterial stiffness as a risk factor for coronary atherosclerosis. Curr Atheroscler Rep 2007; 9: 139-144
61. Zoungas S, Asmar RP. Arterial stiffness, and cardiovascular outcome. Clin Exp Pharmacol Physiol 2007; 34: 647-651
62. Cherney DZ, Perkins BA, Soleymanlou N, Har R, Fagan N, Johansen OE, Woerle HJ, von Eynatten M, Broedl UC. The effect of empagliflozin on arterial stiffness, and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus. Cardiovasc Diabetol 2014; 13: 28
63. Oelze M, Kröller-Schön S, Welschof P, Jansen T, Hausding M, Mikhed Y, Stamm P, Mader M, Zinßius E, Agdauletova S, Gottschlich A, Steven S, Schulz E, Bottari SP, Mayoux E, Münzel T, Daiber A. The sodium-glucose co-transporter 2 inhibitor empagliflozin improves diabetes-induced vascular dysfunction in the streptozotocin diabetes rat model by interfering with oxidative stress, and glucotoxicity. PLoS One 2014; 9: e112394
64. Lin B, Koibuchi N, Hasegawa Y, Sueta D, Toyama K, Uekawa K, Ma M, Nakagawa T, Kusaka H, Kim-Mitsuyama S. Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury, and cognitive dysfunction in obese, and type 2 diabetic mice. Cardiovasc Diabetol 2014; 13: 148
65. Hamouda NN, Sydorenko V, Qureshi MA, Alkaabi JM, Oz M, Howarth FC. Dapagliflozin reduces the amplitude of shortening, and Ca(2+) transient in ventricular myocytes from streptozotocin-induced diabetic rats. Mol Cell Biochem 2015; 400: 57-68
66. Foushee JA, Goodbar NH, Kelly JL, Clarke SL. Cerebrovascular accident in a high-risk patient during the early initiation phase with canagliflozin. Ann Pharmacother 2014; 48: 1066-1069
67. Zinman B, Inzucchi SE, Lachin JM, Wanner C, Ferrari R, Fitchett D, Bluhmki E, Hantel S, Kempthorne-Rawson J, Newman J, Johansen OE, Woerle HJ, Broedl UC. Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME). Cardiovasc Diabetol 2014; 13: 102
68. Neal B, Perkovic V, de Zeeuw D, Mahaffey KW, Fulcher G, Stein P, Desai M, Shaw W, Jiang J, Vercruysse F, Meininger G, Matthews D. Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS) - A randomized placebo-controlled trial. Am Heart J 2013; 166: 217-223
69. Zhang W, Smulders R, Abeyratne A, Dietz A, Krauwinkel W, Kadokura T, Keirns J. Ipragliflozin does not prolong QTc interval in healthy male, and female subjects: A phase I study. Clin Ther 2013; 35: 1150-1161
70. Ring A, Brand T, Macha S, Breithaupt-Groegler K, Simons G, Walter B, Woerle HJ, Broedl UC. The sodium glucose cotransporter 2 inhibitor empagliflozin does not prolong QT interval in a thorough QT (TQT) study. Cardiovasc Diabetol 2013; 12: 70
71. Carlson GF, Tou CK, Parikh S, Birmingham BK, Butler K. Evaluation of the effect of dapagliflozin on cardiac repolarization: A thorough QT/QTc study. Diabetes Ther 2011; 2: 123-132
72. Dziuba J, Alperin P, Racketa J, Iloeje U, Goswami D, Hardy E, Perlstein I, Grossman HL, Cohen M. Modeling effects of SGLT-2 inhibitor dapagliflozin treatment versus standard diabetes therapy on cardiovascular, and microvascular outcomes. Diabetes Obes Metab 2014; 16: 628-635
73. Katsiki N, Papanas N, Fonseca VA, Maltezos E, Mikhailidis DP. Uric acid, and diabetes: Is there a link? Curr Pharm Des 2013; 19: 4930-4937
74. Zoppini G, Targher G, Bonora E. The role of serum uric acid in cardiovascular disease in type 2 diabetic, and nondiabetic subjects: A narrative review. J Endocrinol Invest 2011; 34: 881-886
75. Ferrannini E, Seman L, Seewaldt-Becker E, Hantel S, Pinnetti S, Woerle HJ. A Phase IIb, randomized, placebocontrolled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes. Diabetes Obes Metab 2013; 15: 721-728
76. Wilding JP, Ferrannini E, Fonseca VA, Wilpshaar W, Dhanjal P, Houzer A. Efficacy, and safety of ipragliflozin in patients with type 2 diabetes inadequately controlled on metformin: A dose-finding study. Diabetes Obes Metab 2013; 15: 403-409
77. List JF, Woo V, Morales E, Tang W, Fiedorek FT. Sodiumglucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care 2009; 32: 650-657
78. Lytvyn Y., Š krtić M, Yang GK, Yip PM, Perkins BA, Cherney DZ. Glycosuria-mediated urinary uric acid excretion in patients with uncomplicated type 1 diabetes mellitus. Am J Physiol Renal Physiol 2015; 308: F77-F83
79. Chino Y, Samukawa Y, Sakai S, Nakai Y, Yamaguchi J, Nakanishi T, Tamai I. SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria. Biopharm Drug Dispos 2014; 35: 391-404
80. Oliva RV, Bakris GL. Blood pressure effects of sodiumglucose co-transport 2 (SGLT2) inhibitors. J Am Soc Hypertens 2014; 8: 330-339
81. Baker WL, Smyth LR, Riche DM, Bourret EM, Chamberlin KW, White WB. Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: A systematic review, and meta-analysis. J Am Soc Hypertens 2014; 8: 262-275
82. Barnett AH. Impact of sodium glucose cotransporter 2 inhibitors on weight in patients with type 2 diabetes mellitus. Postgrad Med 2013; 125: 92-100
83. Freeman JS. Review of insulin-dependent, and insulinindependent agents for treating patients with type 2 diabetes mellitus, and potential role for sodium-glucose cotransporter 2 inhibitors. Postgrad Med 2013; 125: 214-226
84. Vasilakou D, Karagiannis T, Athanasiadou E, Mainou M, Liakos A, Bekiari E, Sarigianni M, Matthews DR, Tsapas A. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: A systematic review, and meta-analysis. Ann Intern Med 2013; 159: 262-274
85. Plosker GL. Canagliflozin: A review of its use in patients with type 2 diabetes mellitus. Drugs 2014; 74: 807-824
86. Katsiki N, Papanas N, Mikhailidis DP. Dapagliflozin: More than just another oral glucose-lowering agent? Expert Opin Investig Drugs 2010; 19: 1581-1589
87. Scott LJ. Empagliflozin: A review of its use in patients with type 2 diabetes mellitus. Drugs 2014; 74: 1769-1784
88. Ueta K, Ishihara T, Matsumoto Y, Oku A, Nawano M, Fujita T, Saito A, Arakawa K. Long-term treatment with the Na+-glucose cotransporter inhibitor T-1095 causes sustained improvement in hyperglycemia, and prevents diabetic neuropathy in Goto-Kakizaki Rats. Life Sci 2005; 76: 2655-2668
89. Albertoni Borghese MF, Majowicz MP, Ortiz MC, Passalacqua Mdel R, Sterin Speziale NB, Vidal NA. Expression, and activity of SGLT2 in diabetes induced by streptozotocin: Relationship with the lipid environment. Nephron Physiol 2009; 112: 45-52
90. Freitas HS, Anhê GF, Melo KF, Okamoto MM, Oliveira-Souza M, Bordin S, Machado UF. Na+-glucose transporter-2 messenger ribonucleic acid expression in kidney of diabetic rats correlates with glycemic levels: Involvement of hepatocyte nuclear factor-1alpha expression, and activity. Endocrinology 2008; 149: 717-724
91. Vallon V The proximal tubule in the pathophysiology of the diabetic kidney. Am J Physiol Renal Physiol 2011; 300: R1009-R1022
92. Rahmoune H, Thompson PW, Ward JM, Smith CD, Hong G, Brown J. Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with noninsulin-dependent diabetes. Diabetes 2005; 54: 3427-3434
93. Nakamura N, Matsui T, Ishibashi Y, Yamagishi S. Insulin stimulates SGLT2-mediated tubular glucose absorption via oxidative stress generation. Diabetol Metab Syndr 2015; 7: 48
94. Bonomini F, Rodella LF, Rezzani R. Metabolic syndrome, aging, and involvement of oxidative stress. Aging Dis 2015; 6: 109-120